Form 4: Charles River Labs Executive Acquires Stock and Options
SEC Form 4
Joseph W. LaPlume, EVP at Charles River Laboratories, reports acquisition of stock and options in the company.
Summary
- On May 31, 2024, Joseph W. LaPlume, EVP of Corporate Strategy & Development at Charles River Laboratories, reported acquiring 2,111 shares of common stock at $0 and 4,797 stock options with an exercise price of $208.44.
- Following the transaction, LaPlume beneficially owns 24,612 shares of common stock.
- The stock options vest in four equal installments beginning May 31, 2025, and the restricted stock units vest in four installments beginning May 31, 2025.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating executive compensation, which doesn't inherently suggest positive or negative implications for the company's performance.
Positives
- The acquisition of shares and options by an executive could be seen as a positive signal, indicating confidence in the company's future performance.
Industry Context
Executive stock ownership is a common practice in publicly traded companies and is often used to align management's interests with those of shareholders.
Comparison to Industry Standards
- Executive compensation packages, including stock options and restricted stock units, are standard practice among publicly traded companies like Charles River Laboratories.
- Companies such as Laboratory Corporation of America (LH) and Quest Diagnostics (DGX) also utilize similar equity-based compensation strategies for their executives.
Stakeholder Impact
- The acquisition of shares and options by an executive can positively influence shareholder sentiment, reflecting confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 05/31/2024 | Date of transaction: Acquisition of stock and stock options. |
| 05/31/2025 | First vesting date for 1,199 stock options and 527 restricted stock units. |
| 05/31/2026 | Second vesting date for 1,199 stock options and 528 restricted stock units. |
| 05/31/2027 | Third vesting date for 1,199 stock options and 528 restricted stock units. |
| 05/31/2028 | Final vesting date for 1,200 stock options and 528 restricted stock units. |
| 06/03/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.